EDGAR·FLOW

Arcturus Therapeutics Holdings Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Meiji Seika Pharma purchased $50 million of Arcturus securities at $20.27/share (80% premium to prior pricing), representing 7.9% post-transaction ownership. Concurrently, Arcturus granted Meiji an exclusive license for ARCT-154 technology in an undisclosed therapeutic area and signed an MOU for pandemic preparedness collaboration in Japan. Proceeds will accelerate ARCT-2601 (OTC deficiency) development and validate LUNAR 2.0 platform.
Why this rating

Strategic $50M capital infusion is 15.5% of company market cap; validates platform, funds key pipeline milestone, signals third-party confidence despite undisclosed license scope.

Tradability signal
NO TRADE

No trade: positive news with only -1.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.43% over 4 hrs, n=488). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$9.23 ▼ 0.11%
at our read · unknown
$9.24
+10 min · unknown
$8.79 ▼ 4.85%
+30 min · unknown
$8.86 ▼ 4.17%
+1 hr · unknown
$8.68 ▼ 6.11%
+4 hrs · unknown
$8.51 ▼ 7.89%

The stock had already moved +0.11% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ARCT · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.